chemistry proceedings

MDPI

Proceeding Paper

A Computational Investigation on Potential 5-HT 2C Receptor Inhibitors for Treating Schizophrenia by ADMET Profile Analysis, Molecular Docking, DFT, Network Pharmacology and Molecular Dynamic Simulation †

Mohammed Raihan Uddin, Mahira Rahman, Mosammad Jannatun Nayem Rafin and Joya Datta Ripa *

Department of Pharmacy, University of Science and Technology Chittagong; D-Block, Foy's Lake, Zakir Hossain Road, Chattagram 4202, Bangladesh; raihan.uddin.pharmacy@gmail.com (M.R.U.); mahirarahman13511@gmail.com (M.R.); jannatunnayemrafin31722@gmail.com (M.J.N.R.)

* Correspondence: joya.datta27@ustc.ac.bd

† Presented at the 28th International Electronic Conference on Synthetic Organic Chemistry (ECSOC 2024), 15–30 November 2024; Available online: https://sciforum.net/event/ecsoc-28.

Abstract: Background: Schizophrenia manifests through behavioral abnormalities, suicidal ideation, and neuropsychological deficits. Hence, this study focused on 5-hydroxytryptamine (5-HT 2C) which influenced the modulation of the series of events that lead to Schizophrenia. **Methodology:** Based on the computational study, the potential 5-HT 2C inhibitors such as Ephemeranthoquinone from *Arundina graminifolia*, and Actinodaphnine from *Litsea polyantha* were determined. The candidate ligands were optimized using the Gaussian 16 software package and the DFT 6-31g(d,p) basis set. The interaction between the ligands and proteins was examined with PyRx 0.8. Additionally, pharmacokinetics was assessed using SwissADME, and Protox II for toxicity prediction. Network pharmacology study examined by using STRING database and, the Cytoscape 3.10.1 tool. Moreover, 100 nanoseconds molecular dynamics simulation analysis using Desmond to ensure the stability of these two compounds. **Result:** This computational research observed, ephemeranthoquinone and actinodaphnine are the most selective 5-HT 2C inhibitors due to their docking score, optimization, and molecular dynamics simulation results. **Conclusions:** These compounds are required to be studied further to develop a useful 5-HT 2C inhibitors for the treatment of Schizophrenia.

Keywords: Schizophrenia; 5 HT-C; small molecule inhibitors; Computational Study; Molecular Dynamics Simulation

Citation: Uddin, M.R.; Rahman, M.; Rafin, M.J.N.; Ripa, J.D. A Computational Investigation on Potential 5-HT 2C Receptor Inhibitors for Treating Schizophrenia by ADMET Profile Analysis, Molecular Docking, DFT, Network Pharmacology and Molecular Dynamic Simulation. *Chem. Proc.* **2024**, *6*, x. https://doi.org/10.3390/xxxxx

Academic Editor(s): Name

Published: 15 November 2024



1. Introduction

As a complex mental illness with lifetime prevalence, Schizophrenia (SCZ) impacts about 24 million people globally, equating to 0.32% of the population [1]. Unfortunately, currently available therapies have also failed to tackle SCZ from the molecular level and have come with significant adverse effects which can exacerbate the patient's condition [2]. Given these challenges, natural compounds from medicinal plants present a promising alternative for treating SCZ due to their enrichment in secondary metabolites which have minimal side effects [3].

Our target, the 5-HT 2C receptor at Xq24, belongs to the G protein-coupled receptor (GPCR) superfamily and is mainly associated with serotonin neurotransmission via the HT2CR in the cortico-limbic circuitry pathway that is relevant to SCZ [4]. Additionally, the hypo-glutamatergic basis for certain SCZ symptoms may involve HTR2C, which is present in GABAergic interneurons [5]. Considering the mechanism, computational studies in drug design aim to develop potent antipsychotics from medicinal plants that treat SCZ. Consequently, in this study, molecular docking and simulations were used to understand binding interactions and optimize ligand stability. Further, this approach highlights the potential of network pharmacology and natural compounds in SCZ treatment, hoping for effective drug development through further preclinical studies.

2. Methodology

2.1. Preparation of Protein and Ligands

The RCSB protein databank provided the 3-D structure of the 5-HT 2C protein (PDB ID: 6BQH), which was produced using Discovery Studio 2020 by eliminating co-factors and stabilized using SWISS PDB 4.10. Approximately, sixty CNS-Penetrant compounds were chosen from the IMPPAT database, and retrieved from PubChem in SDF format. Subsequently, the compound library was prepared with the OpenBabel 3.1.1 software.

2.2. ADMET Analysis

After screening plants, the pharmacokinetics (PK), and ADME properties of chosen compounds were estimated using the SwissADME, along with the Protox-II web tool was utilized to analyze the toxicity of the compounds we found.

2.3. Molecular Docking and Network Pharmacology Study

The best binding configuration of the target protein with ligands was found in the PyRx 0.8 tool. As well as the protein-ligand complex's binding pose was observed using

the Pymol 2.5.2. and the Discovery Studio 2021 BIOVIA visualizer. The potential interaction among 5-HT 2C and other proteins was investigated in the STRING database and, the Cytoscape 3.10.1 tool to understand the connection between the top two ligands, the targeted protein, and linked diseases.

2.4. Optimization

The DFT theoretical computations were performed in the gas phase using the 631-G, d,p(+,+) basis set integrating into the Gaussian 9. 4. to observe the stability through medicines' softness (S) and hardness (η) by using the following formula-

$$\eta = \frac{(\varepsilon_{HOMO} - \varepsilon_{LUMO})}{2}; \; s = \frac{\eta}{2}$$

2.5. Molecular Dynamic Simulation

To assure the stability of protein-ligand complex, molecular dynamic simulation was run in the Desmond Dynamics module, available at Schrödinger suit using 100 picoseconds at energy of 1.2, simple point-charge (SPC) water model assigned with an orthorhombic periodic boundary box in a distance of (10 × 10 × 10 A^3), concentration of salt at 0.15 M, Na+ and Cl-ions, OPLS3e force field, at 300.0 K the temperature and 1.01325 bar pressure by calculating of the root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), solvent-accessible surface area (SASA) values, radius of gyration (rRg).

3. Results and Discussion

3.1. Molecular Docking

After performing docking study, we considered only two compounds with highest binding affinity for proceeding further study that are displayed in Table 1. and protein-ligand interaction is present in Figure 1.

Table 1. A list of ligand names and binding affinity with the rmsd value of the top two compounds.

Compounds	Ligands (Pubchem ID and Binding Energy)	Binding Affinity	rmsd/ub	rmsd/lb
Ephemeranthoquinone	Pubchem CID: 10038025, E = 289.17	−9.4	0	0
Actinodaphnine	Pubchem CID: 160502, E = 516.18	−9.3	0	0



(a)



Figure 1. Protein -ligand binding interaction of top two compounds based on binding score. Where (**a**) Ephemranthoquinone, and (**b**) Actinodhapnine.

As for the hydrogen bond in the protein-ligand interaction, the donor and acceptor pairs should be in a distance of 2.7–3.3 Å. Ephemranthoquinone (CID 10038025) and Actinodhapnine (CID 160502) have different hydrogen bond distances in this investigation, illustrates in Table 2.

Table 2. The highest-ranking Protein-ligand complex and the non-bonding interaction of the top two compounds with amino acids residues of 5-HT 2C.

Ligands	Residues	Distances (Å)	Bonding Category	Bonding Type
Ephemranthoquinone	PHE214	3.56622	Hydrogen Bond	Carbon Hydrogen Bond
	N:UNK1—A:PHE223	5.36526	Hydrophobic	Pi-Pi T-shaped
	N:UNK1—A:TRP324	4.8013	Hydrophobic	Pi-Pi T-shaped
	N:UNK1—A:PHE328	4.96592	Hydrophobic	Pi-Pi T-shaped
	A:TRP324—N:UNK1	5.32573	Hydrophobic	Pi-Pi T-shaped
	N:UNK1—A:VAL135	4.38739	Hydrophobic	Pi-Alkyl
Actinodhapnine	N:UNK1:H—A:ALA222:O	2.3234	Hydrogen Bond	Conventional Hydrogen Bond
	N:UNK1:C—A:ASP134:OD1	3.77496	Hydrogen Bond	Carbon Hydrogen Bond
	N:UNK1:C—A:SER138:O	3.14898	Hydrogen Bond	Carbon Hydrogen Bond
	N:UNK1:C—A:TRP324	3.76078	Hydrophobic	Pi-Sigma
	N:UNK1:C—A:TRP324	3.93109	Hydrophobic	Pi-Sigma
	A:TRP324—N:UNK1	5.48968	Hydrophobic	Pi-Pi T-shaped
	A:PHE328—N:UNK1	4.72948	Hydrophobic	Pi-Pi T-shaped

3.2. ADMET Analysis

The pharmacokinetics parameters and toxicological characteristics of top two compounds are enlisted in Tables 3 and 4.

Table 3. ADME analysis of the top two compounds where showed the Molecular weight, Lipophilicity (XLOGP3), Water solubility (Log S (ESOL)), GI absorption, BBB permeant, Lipinski rule of five.

Compounds Name	Molecular Weight (g/mol)	Lipophilicity (XLOGP3)	Water Solubility (Log S (ESOL))	GI Absorption	BBB Permeant	Lipinski
Ephemeranthoquinone	256.25	1.8	−2.73	High	Yes	Yes; 0 violation
Actinodaphnine	311.33	2.45	−3.63	High	Yes	Yes; 0 violation

Table 4. The toxicity profile of the top two compounds.

Compounds	Hepatotoxicity	Carcinogenicity	Mutagenicity	Cytotoxicity
Ephemeranthoquinone	Inactive	Inactive	Inactive	Inactive
Actinodaphnine	Inactive	Inactive	Inactive	Inactive

3.3. Network Pharmacology

The network diagram data of targeted protein with other protein, and top two compounds with other protein interaction were shown in Figure 2a, whereas the interacted protein HTR2A is also responsible for SCZ. Conversely, Figure 2b displays that candidate compounds primarily influenced the genes PIM1, GSK3B, EGFR.



(**a**) Protein-protein interaction (**b**) Protein-ligand interaction

Figure 2. Network Pharmacology analysis of 5-HT 2C protein (**a**) and top two compounds (**b**).

3.4. Optimization

The two global chemical descriptors (softness and hardness) and the orbital energies for the two compounds have been shown in Table 5. Ephemeranthoquinone has the highest softness with lowest HOMO-LUMO gap and hardness indicating more reactive molecule overall. In contrast, Actinodaphnine is less soft than Ephemeranthoqunine and has a somewhat higher hardness and the HOMO-LUGO gap. Moreover, Table 6 presents the compounds' stoichiometry, enthalpy, Gibbs free energy, electronic energy and dipole moment. Figure 3 shows the optimized structures, were Actinodaphnine has the highest energy, enthalpy, and Gibbs free energy, along with the largest dipole moment of 2.220016 Debye, indicating high polarity in real life.

Table 5. The energy of HOMO, LUGO, the gap, hardness, and softness (all units are in Hartree) of Ephemeranthoquinone and Actinodaphnine.

Molecule	HOMO	LUMO	Gap	Hardness	Softness
Actinodaphnine	−0.18821	−0.02135	0.16686	0.08343	11.98
Ephemeranthoquinone	−0.21416	−0.11263	0.10153	0.050765	19.69

Table 6. The stereochemistry, electronic energy, enthalpy, Gibbs free energy (in Hartee), and dipole moment (Debye) of Ephemeranthoquinone and Actinodaphnine.

Name	Stoichiometry	Electron Energy	Enthalpy	Gibbs Free Energy	Dipole Moment (Debye)
Actinodaphnine	C18H17NO4	−1051.46	−1051.46	−1051.52	2.220016
Ephemeranthoquinone	C15H12O4	−879.45	−879.45	−879.51	1.437410



(**a**) (**b**)

Figure 3. The optimization structure of the top two compounds, (**a**) Actinodaphnine, and (**b**) Ephemeranthoquinone.

3.5. Molecular Dynamic Simulation

In this experiment, a 100 ns MD simulation was used to obtain a better knowledge of the conformational changes of the protein with a particular ligand by examining the SASA, the rGyr, RMSF, and RMSD.The two most highly selected compounds, CID 160502 had average RMSD values of 6.39 Å and exhibited reduced fluctuations. Conversely, the average RMSD value of the CID 10038025 compound was 6.97 Å exhibited poorer stability with large fluctuation across the simulation time of 34 to 54 ns. respectively, as demonstrated in Figure 5. Again, from Figure 6, it is clear that a maximum deviation of 14.878 Å is seen between residues in the PHE 46 control 5HT 2C instance. Greater fluctuations are observed twice for the first compound (CID_160502) between residues PHE 46 and LYS 47, approximately 14.768 Å and 12.335 Å, respectively. The second compound (CID_10038025) yields a maximum variation of 14.878 Å in PHE 46 and 13.172 Å in LYS 47. The average value of the first compound (CID_ 160502) is 45.91 Å, and the average value of the second compound (CID_10038025) is 69.41 Å, as shown in Figure 5. The complex system's average SASA value, ranging from 80 Å to 195 Å, indicated that the compounds that were selected were subjected to high quantities of amino acid residues, as depicted in Figure 7. In Figure 8, the stability of the target protein complexes of CID_160502 and CID_10038025 was also examined in terms of rGyr. The average rGyr for the compounds with CID_160502 and CID_10038025 was 3.47Å and 3.31Å, respectively.



Figure 4. RMSD value of top 2 compounds.



Figure 5. RMSF value of top 2 compounds.



Figure 6. SASA value of top 2 compounds.



Figure 7. SASA value of top 2 compounds.

4. Conclusions

In conclusion, because of the exceptional pharmacokinetic properties, good bioavailability characteristics, and noteworthy biochemical interactions of ephemeranthoquinone and actinodaphnine against 5-HT 2C receptors, further research using animal models and preclinical studies should be conducted to examine these two naturally occurring chemicals as latent 5-HT 2C inhibitors in order to produce antipsychotic medications to treat SCZ.

Author Contributions: All authors have equally contributed to this work. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement:

Informed Consent Statement:

Data Availability Statement:

Acknowledgments: This research is supported by Bioinformatics and Molecular Dynamics Simulation Laboratory, Department of Pharmacy, University of Science and Technology Chittagong, Bangladesh.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bhalala, O.G.; Nath, A.P.; Consortium, U.B.E.; Inouye, M.; Sibley, C.R. Identification of expression quantitative trait loci associated with schizophrenia and affective disorders in normal brain tissue. *PLoS Genet*. **2018**, *14*, e1007607.
2. Blokhin, I.O.; Khorkova, O.; Saveanu, R.V.; Wahlestedt, C. Molecular mechanisms of psychiatric diseases. *Neurobiol. Dis.* **2020**, *146*, 105136.
3. Munawar, N.; Ahsan, K.; Ahmad, A. Natural molecules in the treatment of schizophrenia. In *Natural Molecules in Neuroprotection and Neurotoxicity*; Elsevier: Amsterdam, The Netherlands, 2024; pp. 259–280.
4. Stępnicki, P.; Kondej, M.; Kaczor, A.A. Current concepts and treatments of schizophrenia. *Molecules* **2018**, *23*, 2087.
5. Cacabelos, R.; Martínez-Bouza, R. Genomics and pharmacogenomics of schizophrenia. *CNS Neurosci. Ther.* **2011**, *17*, 541–565.